CN1117079C - 取代的异喹啉－3－甲酰胺类化合物,其制备方法及其作为药物的用途 - Google Patents

取代的异喹啉－3－甲酰胺类化合物,其制备方法及其作为药物的用途 Download PDF

Info

Publication number
CN1117079C
CN1117079C CN98121000A CN98121000A CN1117079C CN 1117079 C CN1117079 C CN 1117079C CN 98121000 A CN98121000 A CN 98121000A CN 98121000 A CN98121000 A CN 98121000A CN 1117079 C CN1117079 C CN 1117079C
Authority
CN
China
Prior art keywords
hydrogen
chlorine
formula
hydroxyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN98121000A
Other languages
English (en)
Chinese (zh)
Other versions
CN1218802A (zh
Inventor
K·韦德曼
K－H·巴林哈斯
G·特沙克
U·威尔尼尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibre Gene Inc.
Original Assignee
FIBRE GENE Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FIBRE GENE Inc filed Critical FIBRE GENE Inc
Publication of CN1218802A publication Critical patent/CN1218802A/zh
Application granted granted Critical
Publication of CN1117079C publication Critical patent/CN1117079C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CN98121000A 1997-10-20 1998-10-20 取代的异喹啉－3－甲酰胺类化合物,其制备方法及其作为药物的用途 Expired - Lifetime CN1117079C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19746287A DE19746287A1 (de) 1997-10-20 1997-10-20 Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19746287.1 1997-10-20

Publications (2)

Publication Number Publication Date
CN1218802A CN1218802A (zh) 1999-06-09
CN1117079C true CN1117079C (zh) 2003-08-06

Family

ID=7846053

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98121000A Expired - Lifetime CN1117079C (zh) 1997-10-20 1998-10-20 取代的异喹啉－3－甲酰胺类化合物,其制备方法及其作为药物的用途

Country Status (24)

Country Link
US (1) US6093730A (enExample)
EP (2) EP1538160B1 (enExample)
JP (2) JP3782591B2 (enExample)
KR (1) KR100618922B1 (enExample)
CN (1) CN1117079C (enExample)
AR (1) AR013696A1 (enExample)
AT (2) ATE432940T1 (enExample)
AU (1) AU755714B2 (enExample)
BR (1) BR9804504B1 (enExample)
CA (2) CA2250664A1 (enExample)
CZ (1) CZ337298A3 (enExample)
DE (3) DE19746287A1 (enExample)
DK (2) DK0911340T3 (enExample)
ES (2) ES2245471T3 (enExample)
HU (1) HUP9802422A3 (enExample)
ID (1) ID21115A (enExample)
IL (1) IL126638A0 (enExample)
NO (1) NO312365B1 (enExample)
NZ (1) NZ332363A (enExample)
PL (1) PL192354B1 (enExample)
PT (1) PT911340E (enExample)
SG (1) SG87776A1 (enExample)
TR (1) TR199802106A2 (enExample)
ZA (1) ZA989505B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101497584B (zh) * 2008-01-29 2010-12-22 首都医科大学 异喹啉-3-甲酰氨基酸苄酯及其制备和应用

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528649B2 (en) 2000-05-30 2003-03-04 Neurogen Corporation Imidazoloisoquinolines
US6762318B2 (en) * 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
JP2005524612A (ja) * 2001-12-06 2005-08-18 ファイブローゲン、インコーポレーテッド 内因性エリスロポエチン（ｅｐｏ）を増加させる方法
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
EP2295060B1 (en) 2001-12-06 2018-10-31 Fibrogen, Inc. Treatment or prevention of ischemic or hypoxic conditions
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
CN102718708A (zh) * 2003-06-06 2012-10-10 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
US20060251638A1 (en) * 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US20060276477A1 (en) * 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia
CN101242817B (zh) 2005-06-15 2016-08-31 菲布罗根公司 HIF1α调节剂在治疗癌症中的用途
AU2006326662B2 (en) * 2005-12-09 2011-07-28 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
RU2457204C2 (ru) 2006-01-27 2012-07-27 Файброджен, Инк. Цианоизохинолиновые соединения (варианты), фармацевтическая композиция на их основе, способ ингибирования активности гидроксилазы гипоксия-индуцибельного фактора (hif) и способ лечения и/или профилактики состояния, связанного с hif, и/или состояния, связанного с эритропоэтином, и/или анемии
WO2007101204A1 (en) * 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
KR100949982B1 (ko) * 2006-03-30 2010-03-29 엘지전자 주식회사 비디오 신호를 디코딩/인코딩하기 위한 방법 및 장치
AU2007234408B2 (en) 2006-04-04 2011-05-19 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as HIF modulators
DK3026044T3 (en) 2006-06-26 2019-02-18 Akebia Therapeutics Inc PROLYL HYDROXYLASE INHIBITORS AND METHODS FOR USE
ES2393326T3 (es) 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
CA2672656C (en) 2006-12-18 2012-03-20 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
EP2155680B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Indanone derivatives that inhibit prolyl hydroxylase
CA2683956C (en) 2007-04-18 2012-12-18 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
AU2008248165B2 (en) 2007-05-04 2011-12-08 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
EP2150251B9 (en) 2007-05-04 2013-02-27 Amgen, Inc Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
US8962530B2 (en) * 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
HRP20141038T2 (hr) 2008-04-28 2015-07-03 Janssen Pharmaceutica N.V. Benzoimidazoli kao inhibitori prolil hidroksilaze
CN105037323A (zh) 2008-11-14 2015-11-11 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
HRP20140705T1 (hr) * 2009-07-17 2014-09-12 Japan Tobacco, Inc. Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina
NO2686520T3 (enExample) 2011-06-06 2018-03-17
KR102029951B1 (ko) * 2011-07-22 2019-11-08 베이징 베타 파머수티컬 컴퍼니 리미티드 프로릴 히드록실라제 억제제로서 화합물의 다형체형, 및 이의 용도
MX368157B (es) 2011-10-25 2019-09-20 Janssen Pharmaceutica Nv Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.
JP6129217B2 (ja) 2012-03-09 2017-05-17 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼインヒビターとしての４−ヒドロキシ−イソキノリン化合物
KR20220164068A (ko) 2012-07-16 2022-12-12 피브로겐, 인크. 프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
ES2631655T3 (es) * 2012-07-16 2017-09-01 Fibrogen, Inc. Procedimiento para fabricar compuestos de isoquinolina
US9822135B2 (en) 2012-10-30 2017-11-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 dimerization inhibitors
DK2951159T3 (en) 2013-01-24 2018-11-19 Fibrogen Inc CRYSTALLIC FORMS OF {[1-CYANO-5- (4-CHLORPHENOXY) -4-HYDROXY-ISOQUINOLIN-3-CARBONYL] -AMINO} ACETIC ACID
LT3003284T (lt) 2013-06-06 2020-04-27 Fibrogen, Inc. Hif hidroksilazės inhibitoriaus farmacinės kompozicijos
DK3007695T3 (da) 2013-06-13 2024-03-18 Akebia Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af anæmi
SG10202012791TA (en) 2013-11-15 2021-01-28 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
ES2755941T3 (es) 2014-05-15 2020-04-24 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas
MX2017009417A (es) 2015-01-23 2017-12-07 Akebia Therapeutics Inc Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
PT3277270T (pt) 2015-04-01 2021-12-07 Akebia Therapeutics Inc Composições e métodos de tratamento de anemia
US20180243271A1 (en) * 2015-05-28 2018-08-30 Japan Tobacco Inc. Method for Treating or Preventing Diabetic Nephropathy
AU2016291228B2 (en) * 2015-07-09 2020-04-09 Insmed Incorporated Compositions and methods for treating lung diseases and lung injury
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
US12357628B2 (en) 2018-01-09 2025-07-15 Cornell University Prevention and treatment of organ fibrosis
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
MX2020011845A (es) 2018-05-09 2021-01-15 Akebia Therapeutics Inc Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.
EP3829623A4 (en) * 2018-08-03 2022-10-19 Cornell University METHODS OF REDUCING ABNORMAL SCAR FORMATION
TWI865563B (zh) 2019-07-30 2024-12-11 德商拜耳動物保健有限公司 新穎異喹啉衍生物
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CN112979541B (zh) * 2019-12-17 2022-11-11 浙江大学 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用
CN116120340B (zh) * 2021-11-15 2023-10-31 艾立康药业股份有限公司 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015255A1 (de) * 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
CA2085954A1 (en) * 1991-12-24 1993-06-25 Klaus Weidmann Substituted pyridine n-oxides, processes for their preparation, and their use
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4233124A1 (de) * 1992-10-02 1994-04-07 Hoechst Ag Acylsulfonamido- und Sulfonamidopyridin-2-carbonsäureester sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ATE149486T1 (de) * 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel
ES2101420T3 (es) * 1993-11-02 1997-07-01 Hoechst Ag Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
CA2138929A1 (en) * 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds
IL135495A (en) * 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101497584B (zh) * 2008-01-29 2010-12-22 首都医科大学 异喹啉-3-甲酰氨基酸苄酯及其制备和应用

Also Published As

Publication number Publication date
KR19990037182A (ko) 1999-05-25
ZA989505B (en) 1999-04-20
CZ337298A3 (cs) 1999-05-12
ES2245471T3 (es) 2006-01-01
DE59814365D1 (de) 2009-07-16
NO312365B1 (no) 2002-04-29
AU755714B2 (en) 2002-12-19
CA2251647A1 (en) 1999-04-20
HU9802422D0 (en) 1998-12-28
IL126638A0 (en) 1999-08-17
US6093730A (en) 2000-07-25
JP3782591B2 (ja) 2006-06-07
NO984877L (no) 1999-04-21
CN1218802A (zh) 1999-06-09
AU8941398A (en) 1999-05-06
NO984877D0 (no) 1998-10-19
ATE432940T1 (de) 2009-06-15
EP1538160A1 (de) 2005-06-08
SG87776A1 (en) 2002-04-16
ATE299148T1 (de) 2005-07-15
DK0911340T3 (da) 2005-11-07
BR9804504A (pt) 2001-05-22
EP0911340B1 (de) 2005-07-06
CA2251647C (en) 2011-08-30
HK1019605A1 (en) 2000-02-18
TR199802106A3 (tr) 1999-05-21
BR9804504B1 (pt) 2009-01-13
HUP9802422A2 (hu) 1999-08-30
DK1538160T3 (da) 2009-10-05
JP2006056894A (ja) 2006-03-02
PT911340E (pt) 2005-09-30
JP4691419B2 (ja) 2011-06-01
ID21115A (id) 1999-04-22
HUP9802422A3 (en) 2002-02-28
EP0911340A2 (de) 1999-04-28
EP1538160B1 (de) 2009-06-03
TR199802106A2 (xx) 1999-05-21
PL329274A1 (en) 1999-04-26
PL192354B1 (pl) 2006-10-31
DE59812907D1 (de) 2005-08-11
EP0911340A3 (de) 1999-07-07
ES2328156T3 (es) 2009-11-10
JPH11302257A (ja) 1999-11-02
NZ332363A (en) 2000-04-28
AR013696A1 (es) 2001-01-10
KR100618922B1 (ko) 2007-04-25
CA2250664A1 (en) 1999-04-20
DE19746287A1 (de) 1999-04-22

Similar Documents

Publication Publication Date Title
CN1117079C (zh) 取代的异喹啉－3－甲酰胺类化合物,其制备方法及其作为药物的用途
CN1090188C (zh) 新的苯并萘啶类化合物
CN1282737A (zh) 用于制备取代的喹啉－2－甲酰胺的中间体
CN1449382A (zh) 用作降脂质剂的多芳基羧酰胺类化合物
CN1107144A (zh) 取代的杂环羧酰胺酯，它们的制备及它们作为药物的用途
CN1832742A (zh) 用于治疗心血管疾病的血管紧张素ii受体阻断剂氯沙坦、缬沙坦、坎地沙坦、替米沙坦、依普罗沙坦和奥美沙坦的硝基氧基衍生物
CN1323203A (zh) Fc受体调节剂及其应用
CN1380289A (zh) 可抑制ApoB－分泌物/MTP的酰胺
CN1230110A (zh) 细胞粘连抑制剂
CN1227540A (zh) 具有mmp和tnf抑制活性的异羟肟酸与羧酸的衍生物
CN87101164A (zh) 次膦酸衍生物
CN1107145A (zh) 取代的杂环羧酰胺、它们的制备及作为药物的应用
CN1134148A (zh) 抗血栓形成的脒基苯丙氨酸和脒基吡啶丙氨酸的衍生物
CN1636980A (zh) 二肽腈组织蛋白酶k抑制剂
CN1202902A (zh) 凝血酶抑制剂
CN1649893A (zh) 作为血管肽酶抑制剂的带有n－末端2－酰硫基的二肽衍生物
CN1076928A (zh) 1-[2-芳磺酰基氨基)-1-氧代乙基]哌啶衍生物及其制备和在治疗上的应用
CN85109554A (zh) 氨基水杨酸衍生物及其盐和其药用组合物的制备方法
CN1349542A (zh) 杂环化合物、其中间体和弹性蛋白酶抑制剂
CN1036064C (zh) 新的具有ngf生成促进活性的苯衍生物的制备方法
CN1058019C (zh) 环状氨基酸衍生物
CN1180358A (zh) 作为基质金属蛋白酶抑制剂的桥式吲哚
CN1206213C (zh) N－芳基磺酰氨基酸ω－酰胺
CN1291993A (zh) 用作半胱氨酸活性依赖性酶抑制剂的噻二唑化合物
CN1291197A (zh) 新的乙酰胺衍生物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Applicant after: Awentis Medicines Deutschland GmbH

Applicant before: Hoechst Marion Roussel Deutschland GmbH

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: HOECHST MARION ROUSSEL DEUTSCHLAND GMBH TO: AVENTIS PHARMACY (GERMANY)INTERNATIONAL CO., LTD.

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: FIBRE GENE CO.,LTD.

Free format text: FORMER OWNER: AVENTIS PHARMACY (GERMANY)INTERNATIONAL CO., LTD.

Effective date: 20020803

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20020803

Address after: American California

Applicant after: Fibre Gene Inc.

Address before: Frankfurt, Federal Republic of Germany

Applicant before: Awentis Medicines Deutschland GmbH

C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20030806

CX01 Expiry of patent term